Uncategorized Archives - Page 2 of 2 - Allogene

Jefferies London Healthcare Conference

Post author:Allogene Therapeutics
Post published:November 20, 2024
Post category:Uncategorized

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.

Continue Reading

Stifel 2024 Healthcare Conference

Post author:Allogene Therapeutics
Post published:November 18, 2024
Post category:Uncategorized

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.

Continue Reading

November 18, 2024 8:35 AM EST : Stifel 2024 Healthcare Conference

Post author:Allogene Therapeutics Events
Post published:November 18, 2024
Post category:Uncategorized

Continue Reading

Read more about the article ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Post author:andrewkaretas
Post published:July 15, 2024
Post category:Uncategorized

Continue Reading

Read more about the article FT US Pharma and Biotech Summit

FT US Pharma and Biotech Summit

Post author:andrewkaretas
Post published:June 12, 2024
Post category:Perspectives Uncategorized

Continue Reading

Test

Post author:andrewkaretas
Post published:October 5, 2021
Post category:Uncategorized

Continue Reading